PsyMuKB

PPI network (data source: BioGrid)

A gene is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the mean normalized expression(base 2 log of (TPM+1)) +1 in all brain tissue from GTEx v7 or BrainSpan data.

A protein is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the normalized expression (base 10 log of iBAQ intensity) ≥0.5 in at least one brain tissue from ProteomicsDB data. Otherwise, a gene or protein is determined as either with below-cutoff expressions or no available data.

	The queried gene/protein
	The interacting partner is expressed at mRNA-level
	The interacting partner is expressed at protein-level
	The interacting partner is expressed at both mRNA and protein level
	The interacting partner is with either below-cutoff expressions or no expression data at both mRNA and protein level
	The interacting partner is hit by coding DNMs
	Physical interaction between queried gene/protein and its partner
	Physical interaction between two interacting partners

Symbol A	GeneA coding DNM count	Symbol B	GeneB coding DNM count	Interaction detection method	Publication	Evidence
EXOSC4	1	XRN2	1	genetic interference	Horlbeck MA (2018)	1
XRN1	4	DXO	4	two hybrid	Lehner B (2004)	1
UPF1	8	EXOSC10	1	affinity chromatography technology	Lejeune F (2003)	1
DXO	4	POLR2M	0	affinity chromatography technology	Huttlin EL (2017)	1
EXOSC10	1	DXO	4	two hybrid, two hybrid	Lehner B (2004), Lehner B (2004)	2
DXO	4	PRMT6	2	two hybrid	Weimann M (2013)	1
POLR2M	0	RPAP2	3	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
EXOSC7	0	DXO	4	two hybrid	Lehner B (2004)	1
DXO	4	3493	0	affinity chromatography technology	Huttlin EL (2015)	1
DXO	4	XRN2	1	two hybrid, two hybrid	Lehner B (2004), Lehner B (2004)	2
EXOSC4	1	DXO	4	two hybrid	Lehner B (2004)	1
XRN1	4	EXOSC10	1	two hybrid	Lehner B (2004)	1
POLR2M	0	RECQL5	3	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
UPF1	8	XRN1	4	affinity chromatography technology, affinity chromatography technology, affinity chromatography technology	Lejeune F (2003), Franks TM (2010), Isken O (2008)	3
XRN2	1	EXOSC10	1	two hybrid	Lehner B (2004)	1
DXO	4	RPAP2	3	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
UPF1	8	EXOSC4	1	affinity chromatography technology	Lejeune F (2003)	1
EXOSC7	0	EXOSC10	1	two hybrid, affinity chromatography technology, biochemical, affinity chromatography technology	Lehner B (2004), Huttlin EL (2015), Wan C (2015), Huttlin EL (2017)	4
EXOSC7	0	EXOSC4	1	two hybrid, affinity chromatography technology, biochemical, affinity chromatography technology, biochemical, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology	Raijmakers R (2002), Tomecki R (2010), Havugimana PC (2012), Huttlin EL (2015), Wan C (2015), Hein MY (2015), Huttlin EL (2017), Boldt K (2016)	8
DXO	4	3494	0	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
POLR2M	0	RPRD1A	2	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
DXO	4	ARMC5	3	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
UPF1	8	DXO	4	two hybrid	Lehner B (2004)	1
DXO	4	DXO	4	two hybrid	Lehner B (2004)	1
RPRD1A	2	DXO	4	biochemical	Wan C (2015)	1
DXO	4	RECQL5	3	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
EXOSC4	1	EXOSC10	1	affinity chromatography technology, biochemical, two hybrid, two hybrid, biochemical, affinity chromatography technology	Tomecki R (2010), Havugimana PC (2012), Lehner B (2004), Lehner B (2004), Wan C (2015), Hein MY (2015)	6